CAJ | 학술논문

近年随着荧光原位杂交(FISH)等技术的应用,多发性骨髓瘤(MM)染色体异常检出率明显提高,其中13号染色体异常最为常见,约占50%.定位于13号染色体上的肿瘤抑制基因和微小RNA在MM的发病机制中发挥重要作用.在过去的10年里研究者普遍认为13号染色体缺失(△13)是MM的独立预后不良因素,但目前越来越多的研究证实其预后价值有赖于其他染色体的异常,且随着新型药物的不断应用,其不良预后可以被逆转.
근년수착형광원위잡교(FISH)등기술적응용,다발성골수류(MM)염색체이상검출솔명현제고,기중13호염색체이상최위상견,약점50%.정위우13호염색체상적종류억제기인화미소RNA재MM적발병궤제중발휘중요작용.재과거적10년리연구자보편인위13호염색체결실(△13)시MM적독립예후불량인소,단목전월래월다적연구증실기예후개치유뢰우기타염색체적이상,차수착신형약물적불단응용,기불량예후가이피역전.
With the development of FISH and other technique, the detection rate of chromosome abnormalities in multiple myeloma (MM) were increased. Chromosome 13 abnormalities is most common feature (about 50 %). The tumor suppressor gene and micro RNA on chromosome 13 play an important role on pathogenesis of MM. In the last decade, it is widely believed that chromosome 13 abnormalities is independent poor prognosis factor, but the recent more studies conform that its prognosis value is dependent on the other chromosome abnormalities. It is found that the new drugs such as bortezomib appear to reverse the poor prognosis conferred by chromosome 13 deletion.